Pemetrexed in the treatment of selected solid tumors

Research output: Contribution to journalReview articlepeer-review

11 Scopus citations


The novel agent pemetrexed inhibits thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase. Significant activity has been seen in completed phase II trials of pemetrexed in non-small cell lung cancer and breast cancer. Pemetrexed is also active in combination with other agents such as gemcitabine, cisplatin, and carboplatin. In addition, this agent shows promising activity in bladder, head and neck, esophageal, renal, and cervical carcinomas. Preliminary results of studies in these tumor types are reviewed.

Original languageEnglish (US)
Pages (from-to)50-53
Number of pages4
JournalSeminars in oncology
Issue number2 SUPPL. 5
StatePublished - 2002

ASJC Scopus subject areas

  • Hematology
  • Oncology


Dive into the research topics of 'Pemetrexed in the treatment of selected solid tumors'. Together they form a unique fingerprint.

Cite this